Search LNTH
Lantheus Holdings, Inc.
Nasdaq · CIK 1521036
Last close99.96
Daily change+0.31 (0.31%)
10 Years gain+1114.58%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
LNTH · STANDARD
SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Fiscal year end 1231
Fundamental
78.5Momentum
5.6Acceleration
3.4Confidence
91.0Annual Revenue13
Quarterly Revenue50
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth10.3 / 25
Quality21.6 / 25
Capital Efficiency18.5 / 20
Balance Sheet15.0 / 15
Shareholder Economics9.1 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 5.5177%.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 3.2101 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 8.8755 percentage points.
ROIC declining · MEDIUMROIC declined by 28.4322 percentage points.
Key Metrics
Revenue Growth TTM0.79%OK
Revenue CAGR 3Y18.13%OK
Gross Margin61.28%OK
Operating Margin20.5%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC25.11%OK
Incremental Operating Margin 3Y26.03%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-5.52%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.54B | $941.95M | $310.83M | $390.14M | n/a | 61.1% | 20.16% | n/a | 50.98% | 68.44M |
| 2025 FY Dec 31, 2024 | $1.53B | $988.29M | $456.98M | $544.75M | n/a | 64.43% | 29.79% | n/a | 237.29% | 71.65M |
| 2025 FY Dec 31, 2023 | $1.30B | $709.54M | $364.64M | $305.26M | n/a | 54.73% | 28.13% | n/a | 83.7% | 70.24M |
| 2024 FY Dec 31, 2022 | $935.06M | $581.70M | $36.20M | $281.78M | n/a | 62.21% | 3.87% | n/a | 6.08% | 70.67M |
| 2023 FY Dec 31, 2021 | $425.21M | $187.70M | -$60.83M | $53.92M | $53.92M | 44.14% | -14.3% | 12.68% | -8.05% | 67.49M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.53B | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-336795, 0001193125-25-268113 |
| Revenue Growth TTM | 0.79% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-336795, 0001193125-25-268113 |
| Revenue CAGR 3Y | 18.13% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-073498 |
| Revenue CAGR 5Y | 35.35% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-073498 |
| Gross Profit CAGR 3Y | 17.43% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-073498 |
| Operating Income Growth | -29.66% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001193125-26-336795, 0001193125-25-268113 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 61.28% | Gross Profit / Revenue | OK | 0001193125-26-336795, 0001193125-25-268113 |
| Operating Margin | 20.5% | Operating Income / Revenue | OK | 0001193125-26-336795, 0001193125-25-268113 |
| ROIC | 25.11% | NOPAT / Average Invested Capital | OK | 0001193125-26-336795, 0001193125-25-268113 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-336795 |
| Current Ratio | 3.06x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 851.22x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-336795 |
| Revenue per Diluted Share | $22.62 | Revenue / Diluted Shares | OK | 0001193125-26-336795, 0001193125-25-268113 |